Medicines Technology Catapult

Medicines Discovery Catapult (MDC) is a UK-based national facility and not-for-profit company that reshapes drug discovery to deliver better treatments for patients. Headquartered at Alderley Park, MDC provides the life sciences community with access to advanced laboratory technologies, drug discovery expertise, and collaborative R&D programs. The organization focuses on de-risking early-stage drug discovery by applying predictive biological models, translational imaging, and informatics. MDC partners with SMEs, academia, charities, and the pharmaceutical industry to transform scientific breakthroughs into investable and clinically viable products. Key national initiatives led by MDC include the Psychiatry Consortium, the PACE antimicrobial resistance program, and the National PET Imaging Platform (NPIP). Through these efforts, MDC has helped secure over £1.3 billion in private and public investment for the UK life sciences sector.